Middle East and Africa Allergy Immunotherapies Market

Market Introduction

Allergen immunotherapy, also known as hypo-sensitization or desensitization, is a medical treatment for allergies. Measured doses of allergens are given to the patient resulting in reduced inflammation, which causes immune system to become less sensitive to the substance by blocking antibody function. Allergy immunotherapy primary therapeutic goals include reducing symptoms, reducing symptomatic medication use, and improving allergy-related quality of life.

Middle East and Africa Allergy Immunotherapies Strategic Insights

Strategic insights for the Middle East and Africa Allergy Immunotherapies provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Allergy Immunotherapies Report Scope

Middle East and Africa Allergy Immunotherapies Regional Insights

The geographic scope of the Middle East and Africa Allergy Immunotherapies refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Middle East & Africa Allergy immunotherapies market was valued at US$ 137.87 million in 2019 and is projected to reach US$ 297.62 million by 2027; it is expected to grow at a CAGR of 10.2% during the forecast period. The Middle East & Africa allergy immunotherapies market is expected to grow owing to key driving factors such as the increasing prevalence of allergic disorders and technological advancements in sublingual dosage formulations. However, drawbacks associated with the use of allergy immunotherapies, restricted healthcare spending and regulatory variations across regions is likely to hamper the growth of the market during the forecast period.

Key Market Segments

The Middle East and Africa Allergy immunotherapies market, based on treatment is segmented into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). In 2019, the Subcutaneous Immunotherapy (SCIT) segment held the largest share of the market, however, the Sublingual Immunotherapy (SLIT) segment is expected to grow at the fastest rate during the forecast period. Based on Allergy Type, the Middle East and Africa allergy immunotherapies market was segmented into Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others. The Allergic Rhinitis segment held the highest share of the Allergy immunotherapies market in 2019. Moreover, the same segment is anticipated to witness growth at a significant rate during the forecast period.

Based on distribution channel, market is segmented into, hospital pharmacy, retail pharmacy and online pharmacy. In 2019, the hospital pharmacy settings segment held the largest share of the market and the same pharmacy segment is expected to grow at the fastest rate during the forecast period.

Major Sources and Companies Listed

Some of the major primary and secondary sources for Middle East & Africa allergy immunotherapies market included in the report are Celsion Corporation; World Allergy Organization (WAO); World Health Organization (WHO); Saudi Society of Allergy, Asthma and Immunology and Allergy Society of South Africa (ALLSA).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of the Middle East & Africa allergy immunotherapy market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different Middle East & Africa allergy immunotherapy segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Middle East & Africa allergy immunotherapy market, providing a clear picture of future opportunities that will help Analyse, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Middle East & Africa immunotherapy market.

Middle East & Africa ALLERGY IMMUNOTHERAPIES MARKET SEGMENTATION

By Treatment

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)

By Allergy Type

• Allergic Rhinitis
• Asthma
• Food Allergy
• Venom Allergy
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Company Profiles

• HAL Allergy B.V.
• ALK Abello A/S
• Stallergenes Greer
• Anergis
• Circassia